Nuvectis Pharma, Inc. NVCT · SEC Filings

website

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of target...

Price21.02

Market Cap722.85 M

Float26.41 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights

Nov 4, 2026

8-K

Nuvectis Pharma, Inc. Establishes New $200 Million "At the Market" Offering Program

Aug 21, 2026

8-K

Nuvectis Pharma Reports Q2 2026 Financial Results and Strategic Pipeline Expansion

Aug 4, 2026

8-K

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Jun 30, 2026

8-K

Nuvectis Pharma, Inc. Reduces Sales Agreement Capacity and Suspends Prospectus

Jun 29, 2026

8-K

Nuvectis Pharma Expands Pipeline with Exclusive Ex-China Licensing of Two Clinical-Stage Compounds from Haisco

Jun 23, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 30, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Cantor

Jun 29, 2026

424B5

May 2025 ATM

May 9, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 6, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 4, 2025

424B4

OFFERING | Shares amount: 3,200,000 | Share price: $5.00 | Offering amount: $16,000,000.00

Feb 7, 2022

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 31, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 23, 2026

CORRESP

Form CORRESP - Correspondence

Feb 18, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 18, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 30, 2023

CORRESP

Form CORRESP - Correspondence

Mar 27, 2023